MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- AJANTA PHARMA - MYLAN (US)
AJANTA PHARMA vs MYLAN (US) - Comparison Results
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 AJANTA PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AJANTA PHARMA Mar-19 |
MYLAN Dec-18 |
AJANTA PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,422 | 3,586 | - | |
| Low | Rs | 898 | 1,974 | - | |
| Sales per share (Unadj.) | Rs | 233.5 | 1,650.2 | - | |
| Earnings per share (Unadj.) | Rs | 44.0 | 44.8 | - | |
| Cash flow per share (Unadj.) | Rs | 52.2 | 353.8 | - | |
| Dividends per share (Unadj.) | Rs | 9.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 255.1 | 1,785.2 | - | |
| Shares outstanding (eoy) | m | 88.02 | 514.50 | - | |
| Bonus/Rights/Conversions | BB | - | - | ||
| Price / Sales ratio | x | 5.0 | 1.7 | 294.8% | |
| Avg P/E ratio | x | 26.4 | 62.0 | 42.5% | |
| P/CF ratio (eoy) | x | 22.2 | 7.9 | 283.0% | |
| Price / Book Value ratio | x | 4.5 | 1.6 | 292.0% | |
| Dividend payout | % | 20.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 102,081 | 1,430,334 | 7.1% | |
| No. of employees | `000 | 6.8 | 35.0 | 19.4% | |
| Total wages/salary | Rs m | 4,307 | 0 | - | |
| Avg. sales/employee | Rs Th | 3,022.6 | 24,257.3 | 12.5% | |
| Avg. wages/employee | Rs Th | 633.4 | 0 | - | |
| Avg. net profit/employee | Rs Th | 569.1 | 658.7 | 86.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 20,554 | 849,006 | 2.4% | |
| Other income | Rs m | 211 | 0 | - | |
| Total revenues | Rs m | 20,765 | 849,006 | 2.4% | |
| Gross profit | Rs m | 5,664 | 219,691 | 2.6% | |
| Depreciation | Rs m | 721 | 158,967 | 0.5% | |
| Interest | Rs m | 12 | 40,834 | 0.0% | |
| Profit before tax | Rs m | 5,143 | 19,890 | 25.9% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 1,273 | -3,164 | -40.2% | |
| Profit after tax | Rs m | 3,870 | 23,054 | 16.8% | |
| Gross profit margin | % | 27.6 | 25.9 | 106.5% | |
| Effective tax rate | % | 24.8 | -15.9 | -155.6% | |
| Net profit margin | % | 18.8 | 2.7 | 693.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,812 | 474,084 | 2.5% | |
| Current liabilities | Rs m | 3,776 | 345,660 | 1.1% | |
| Net working cap to sales | % | 39.1 | 15.1 | 258.5% | |
| Current ratio | x | 3.1 | 1.4 | 228.1% | |
| Inventory Days | Days | 77 | 84 | 92.6% | |
| Debtors Days | Days | 82 | 93 | 87.4% | |
| Net fixed assets | Rs m | 14,398 | 164,693 | 8.7% | |
| Share capital | Rs m | 175 | 452 | 38.8% | |
| Net worth | Rs m | 22,452 | 918,470 | 2.4% | |
| Long term debt | Rs m | 7 | 991,324 | 0.0% | |
| Total assets | Rs m | 26,962 | 2,463,693 | 1.1% | |
| Interest coverage | x | 444.3 | 1.5 | 29,879.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
| Sales to assets ratio | x | 0.8 | 0.3 | 221.2% | |
| Return on assets | % | 14.4 | 2.6 | 555.1% | |
| Return on equity | % | 17.2 | 2.5 | 686.7% | |
| Return on capital | % | 23.0 | 3.2 | 721.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 3,748 | 176,424 | 2.1% | |
| From Investments | Rs m | -2,228 | -91,192 | 2.4% | |
| From Financial Activity | Rs m | -1,475 | -82,188 | 1.8% | |
| Net Cashflow | Rs m | 45 | 1,462 | 3.1% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 75.34 Rs / USD
Compare AJANTA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare AJANTA PHARMA With: ALEMBIC PHARMA TTK HEALTHCARE PFIZER WYETH FRESENIUS KABI ONCO.
Today's Market
Sensex, Nifty Recover From Day's Low to End Strong; JSW Steel and ICICI Bank Among Top Nifty Gainers(Closing)
Indian share markets recouped early losses during afternoon deals and ended today's volatile session higher.
Related Views On News
AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)
Feb 5, 2021 | Updated on Feb 5, 2021For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.
AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Jun 24, 2019 | Updated on Jun 24, 2019Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.
More Views on NewsMost Popular
India: Recovery Stalled by Vaccine Games? (The Honest Truth)
Apr 13, 2021Ajit Dayal on how India's vaccine strategy will impact the markets.
Top 3 Nifty ETFs to Buy Now (Fast Profits Daily)
Apr 20, 2021In this video I tell you the three Nifty ETFs I think are the best.
A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)
Apr 15, 2021Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
11x Bankruptcy to Bluechip Stock: A Rare India Revival Story (Profit Hunter)
Apr 16, 2021There is no stopping this 11-bagger stock from significant upside.
Why Did the Market Crash on Monday? (Fast Profits Daily)
Apr 13, 2021In this video, I'll you what I think is the real reason behind yesterday's market crash.
More
